Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections.

Authors :: Saunders IM
Lahoti A
Chemaly RF
Trevino C
Westmoreland M
Hosing C
Source :: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2016 Apr; Vol. 22 (2), pp. 325-31. Date of Electronic Publication: 2014 Dec 07.
Publication Year :: 2016
Abstract: Cidofovir, a nucleoside analog of deoxycytidine monophosphate, is a water-soluble polar molecule that exhibits antiviral activity against a broad range of DNA viruses. Cidofovir for injection is approved for the treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. The safety and efficacy of topical cidofovir has been described in a limited number of patients. We present two cases of multidrug-resistant herpes simplex virus infections that responded to topical cidofovir therapy yet resulted in irreversible acute kidney injury.<br /> (© The Author(s) 2014.)

Language :: English
ISSN :: 1477-092X
Volume :: 22
Issue :: 2
Database :: MEDLINE
Journal :: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Publication Type :: Academic Journal
Accession number :: 25488905
Full Text :: https://doi.org/10.1177/1078155214560921

Full Text Access

Tools